Related Experiment Video
Updated: Apr 22, 2026
11:59
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
6.8K
Quantification of mixed chimerism allows early therapeutic interventions
Jóice Merzoni1, Gisele Menezes Ewald2, Alessandra Aparecida Paz1
1Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.
Revista Brasileira De Hematologia E Hemoterapia
|October 12, 2014
Summary
Monitoring mixed chimerism after hematopoietic stem cell transplantation (HSCT) is crucial. Quantitative detection can guide early intervention for myelodysplastic syndrome relapse, improving patient outcomes.
Area of Science:
- Hematology
- Transplantation Immunology
- Oncology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Allogeneic hematopoietic stem cell transplantation (HSCT) offers a curative option for MDS.
- Long-term monitoring is essential to detect disease relapse post-HSCT.
Purpose of the Study:
- To evaluate the role of quantitative chimerism analysis in managing MDS post-HSCT.
- To assess the effectiveness of donor lymphocyte infusion (DLI) in treating relapsed MDS.
Main Methods:
- A case study of a 53-year-old woman with MDS undergoing HSCT.
- Short tandem repeat (STR) analysis for chimerism assessment at multiple time points.
- Administration of donor lymphocyte infusions (DLIs) for relapsed disease.
Main Results:
- Initial HSCT led to full chimerism, followed by relapse indicated by mixed chimerism (52.62%).
- First DLI successfully restored full chimerism, but a subsequent relapse occurred (mixed chimerism 64.25%).
- Second DLI failed; a second HSCT was required, ultimately achieving full chimerism.
Conclusions:
- Quantitative detection of mixed chimerism is a vital diagnostic tool for early identification of MDS relapse.
- Monitoring chimerism levels can guide timely therapeutic interventions, including DLIs and repeat HSCT.
- Early detection and intervention are key to improving outcomes in patients with MDS post-HSCT.
